We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of ...

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.

The accompanying press release dated February 13, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...

"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

Reports Q3 revenue $994.2M, consensus $990.71M. “Dexcom’s (DXCM) third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an ...

The accompanying press release dated May 1, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...